# Revelation Biosciences, Inc.: overview REVB · Nasdaq · CIK 1810560 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/revb.md) · [Financials](/companies/revb/financials.md) · [Filings](/companies/revb/filings.md) · [Insiders](/companies/revb/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(40.15)](/filings/0001193125-25-269450.md) | not reported | [(25.34)](/filings/0001193125-26-211871.md) | [(28.04)](/filings/0001193125-26-337967.md) | [(1.77)](/filings/0001193125-25-269450.md) | not reported | [(2.71)](/filings/0001193125-26-211871.md) | [(0.87)](/filings/0001193125-26-337967.md) | | Free cash flow | $k | [(9,275) d](/filings/0001193125-25-269450.md) | [(3,765) d](/filings/0001193125-26-076552.md) | not reported | not reported | not reported | not reported | [(3,287)](/filings/0001193125-26-211871.md) | [(2,597) d](/filings/0001193125-26-337967.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(42.50)](/filings/0000950170-23-011000.md) | [(149.20)](/filings/0000950170-24-108793.md) | [(8.44)](/filings/0000950170-25-034584.md) | [(1052.16)](/filings/0001193125-26-076552.md) | [(23.95)](/filings/0001193125-26-076552.md) | | Free cash flow | $m | [(11.2)](/filings/0000950170-23-011000.md) | not reported | not reported | [(18.3)](/filings/0001193125-26-076552.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/revb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Linden Advisors LP](/funds/1279396.md) | 2026-06-30 | $2.4k | 337,752 | | Reduced −358 | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $2.0k | 246,934 | | Reduced −600 | | [Pine Valley Investments Ltd Liability Co](/funds/1975417.md) | 2026-06-30 | $1.9k | 236,857 | | Not compared | | [T3 Companies, LLC](/funds/2052441.md) | 2026-06-30 | $1.6k | 198,090 | | Unchanged | | [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $792 | 99,050 | | Reduced −500 | | [WOLVERINE ASSET MANAGEMENT LLC](/funds/1279891.md) | 2026-06-30 | $433 | 54,752 | | Unchanged | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $395 | 50,000 | | Unchanged | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $262 | 42,266 | | New +42,266 | | [Soltis Investment Advisors LLC](/funds/1802530.md) | 2026-06-30 | $178 | 22,500 | | Reduced −25,000 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $116 | 18,716 | | Reduced −13,684 | ## Recent filings [All 387 filings](/companies/revb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-19 | 17:07 ET | [8-K](/filings/0001193125-26-357120.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-357120 | | 2026-08-06 | 16:19 ET | [8-K](/filings/0001193125-26-338097.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338097 | | 2026-08-06 | 16:07 ET | [10-Q](/filings/0001193125-26-337967.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337967 | | 2026-07-13 | 16:05 ET | [8-K](/filings/0001193125-26-302008.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-302008 | | 2026-06-24 | 16:47 ET | [8-K](/filings/0001193125-26-281200.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-281200 | | 2026-06-01 | 17:26 ET | [8-K](/filings/0001193125-26-251784.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-251784 | | 2026-05-11 | 09:56 ET | [DEF 14A](/filings/0001193125-26-215804.md) | Proxy statement, period 2026-06-24 | 0001193125-26-215804 | | 2026-05-07 | 16:23 ET | [8-K](/filings/0001193125-26-212064.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-212064 | | 2026-05-07 | 16:06 ET | [10-Q](/filings/0001193125-26-211871.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211871 | | 2026-03-19 | 16:18 ET | [8-K](/filings/0001193125-26-116012.md) | 3.03 Change to security holders’ rights; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-116012 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076552.md), filed Feb 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1810560 - Tickers: REVB, REVBW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.